Back to search results

Phase IB/II of CPX-351 for Relapse Prevention in AML

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Acute Myeloid Leukemia (AML) in Remission

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Courtney Brown, RN) · courtney.brown@georgetown.edu · 202-687-0354
    Contact: Principal Investigator (Kimberley Doucette, MD)

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

    Contact: Study coordinator (Oncology Clinical Research Referral Office) · OncologyResearchReferral@hmhn.org · 551-996-1777
    Contact: Principal Investigator (James McCloskey, MD)

  • University of Pennsylvania, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Fatme Chaloub) · Fatme.Chaloub@pennmedicine.upenn.edu · 215-906-8435
    Contact: Principal Investigator (Catherine Lai, MD)
Study leads

  • Kimberley Doucette, MD

    Principal Investigator

    Georgetown University

View source on ClinicalTrials.gov(opens in a new tab)